Tasly Pharmaceutical Group Co Ltd Asset Resilience Ratio
Tasly Pharmaceutical Group Co Ltd asset resilience ratio. Tasly Pharmaceutical Group Co Ltd (600535) has an Asset Resilience Ratio of 14.98% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Tasly Pharmaceutical Group Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tasly Pharmaceutical Group Co Ltd (2004–2025)
Asset resilience ratio of Tasly Pharmaceutical Group Co Ltd from 2004 to 2025. This chart shows how Tasly Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Read debt load of Tasly Pharmaceutical Group Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tasly Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Tasly Pharmaceutical Group Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.29 Billion | 14.98% |
| Total Liquid Assets | CN¥2.29 Billion | 14.98% |
Asset Resilience Insights
- Moderate Liquidity: Tasly Pharmaceutical Group Co Ltd has 14.98% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Tasly Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tasly Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Tasly Pharmaceutical Group Co Ltd Asset Resilience Ratio by Year (2004–2025)
Tasly Pharmaceutical Group Co Ltd asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Tasly Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.09% | CN¥1.39 Billion ≈ $204.00 Million |
CN¥15.34 Billion ≈ $2.24 Billion |
+5.58pp |
| 2024-12-31 | 3.50% | CN¥524.72 Million ≈ $76.78 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+1.70pp |
| 2023-12-31 | 1.80% | CN¥300.71 Million ≈ $44.00 Million |
CN¥16.71 Billion ≈ $2.45 Billion |
-5.05pp |
| 2022-12-31 | 6.85% | CN¥1.12 Billion ≈ $164.62 Million |
CN¥16.43 Billion ≈ $2.40 Billion |
-2.15pp |
| 2021-12-31 | 8.99% | CN¥1.49 Billion ≈ $217.66 Million |
CN¥16.54 Billion ≈ $2.42 Billion |
+8.13pp |
| 2020-12-31 | 0.87% | CN¥142.92 Million ≈ $20.91 Million |
CN¥16.49 Billion ≈ $2.41 Billion |
+0.62pp |
| 2019-12-31 | 0.25% | CN¥59.39 Million ≈ $8.69 Million |
CN¥24.01 Billion ≈ $3.51 Billion |
-0.38pp |
| 2018-12-31 | 0.63% | CN¥158.30 Million ≈ $23.16 Million |
CN¥25.17 Billion ≈ $3.68 Billion |
-1.94pp |
| 2017-12-31 | 2.57% | CN¥552.66 Million ≈ $80.87 Million |
CN¥21.53 Billion ≈ $3.15 Billion |
+1.00pp |
| 2016-12-31 | 1.56% | CN¥267.90 Million ≈ $39.20 Million |
CN¥17.13 Billion ≈ $2.51 Billion |
-0.19pp |
| 2015-12-31 | 1.76% | CN¥270.50 Million ≈ $39.58 Million |
CN¥15.41 Billion ≈ $2.26 Billion |
+1.39pp |
| 2014-12-31 | 0.36% | CN¥46.85 Million ≈ $6.86 Million |
CN¥12.92 Billion ≈ $1.89 Billion |
-0.47pp |
| 2013-12-31 | 0.83% | CN¥84.96 Million ≈ $12.43 Million |
CN¥10.21 Billion ≈ $1.49 Billion |
+0.58pp |
| 2012-12-31 | 0.25% | CN¥19.00 Million ≈ $2.78 Million |
CN¥7.49 Billion ≈ $1.10 Billion |
-0.36pp |
| 2006-12-31 | 0.61% | CN¥20.04 Million ≈ $2.93 Million |
CN¥3.26 Billion ≈ $477.01 Million |
-2.66pp |
| 2005-12-31 | 3.27% | CN¥90.08 Million ≈ $13.18 Million |
CN¥2.75 Billion ≈ $403.06 Million |
+2.82pp |
| 2004-12-31 | 0.46% | CN¥10.02 Million ≈ $1.47 Million |
CN¥2.20 Billion ≈ $322.08 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more